Literature DB >> 21933694

MAGE-A family: attractive targets for cancer immunotherapy.

Meixiang Sang1, Yishui Lian, Xinliang Zhou, Baoen Shan.   

Abstract

The melonoma-associated antigens family A (MAGE-A) belongs to cancer/testis antigens (CTA) that are expressed in a wide variety of malignant tumors but not in normal adult tissues except for testis. Interestingly, germ cells do not express MHC class I antigen, implying that these gene products should be ideal targets for cancer immunotherapy. The strict tumor-specific expression of MAGE-As has led to several immunotherapeutic trials targeting some of these proteins. In this review, we briefly described the expression and activation mechanism of MAGE-As in cancer. We also summarized the biological functions of MAGE-As in cell progress and the progress of the cancer immunotherapy targeting MAGE-A family.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933694     DOI: 10.1016/j.vaccine.2011.09.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Cancer Progression Prediction Using Gene Interaction Regularized Elastic Net.

Authors: 
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2015-12-23       Impact factor: 3.710

2.  Ing1 functions in DNA demethylation by directing Gadd45a to H3K4me3.

Authors:  Andrea Schäfer; Emil Karaulanov; Ulrike Stapf; Gabi Döderlein; Christof Niehrs
Journal:  Genes Dev       Date:  2013-02-01       Impact factor: 11.361

3.  MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation.

Authors:  Till J Meyer; Stefan Hartmann; Gisela Wohlleben; Muna Brisam; Axel Seher; Alexander C Kübler; Bülent Polat; Urs D A Müller-Richter
Journal:  Mol Clin Oncol       Date:  2018-01-19

4.  Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress.

Authors:  Leticia Y Peche; María F Ladelfa; María F Toledo; Miguel Mano; Julieta E Laiseca; Claudio Schneider; Martín Monte
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

5.  Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma.

Authors:  Liang Han; Bin Jiang; Hao Wu; Shu Zhang; Xueguan Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny.

Authors:  Christopher S Willett; Elizabeth M Wilson
Journal:  J Mol Evol       Date:  2018-03-24       Impact factor: 2.395

Review 7.  Dendritic cell-based cancer immunotherapy for colorectal cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Keisuke Saito; Shinichiro Takami; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

8.  Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients.

Authors:  Eman Abd-Elkader Abd-Elsalam; Nadia A Ismaeil
Journal:  Med Oncol       Date:  2014-10-15       Impact factor: 3.064

9.  Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Authors:  Viswanath Gunda; Alexandria P Cogdill; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

10.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.